eMarketer: Wegovy pill Q3 sales outpace Foundayo as Novo leads orals
Wegovy pill sales hit about $811m in Q3 (up 53% quarter-on-quarter), while Lilly's Foundayo nearly doubled to $184m but missed forecasts. IQVIA data cited for the week ending 23 October put Wegovy pill scripts at 183,000 versus 63,110 for Foundayo, even as Lilly's injectable Zepbound still dominates shots.
Source: eMarketer (5 Nov 2026).